Usefulness of recombinant human TSH-aided radioiodine doses administered in patients with differentiated thyroid carcinoma

the published studies confirming the safety and efficacy of rhtsh for diagnostic purposes have led to an increased interest in its use for preparation for radioiodine (ri) dose administration in patients with recurrent or persistent differentiated thyroid carcinoma (dtc). in order to establish the efficacy of ri therapy after rhtsh, we have reviewed 39 rhtsh-aided radioiodine treatment in a series of 28 dtc patients. patients were divided into two groups: gi (n=17), with previous thyroid bed uptake and undetectable thyroglobulin (tg) levels under levothyroxine treatment and gii (n=11), with proven metastatic local or distant disease. median follow-up after the first rhtsh-aided radioiodine treatment was 32 ± 13 months (range 8 to 54 months). sixteen patients (94%) in gi were rendered disease free and one patient was shown to have persistent disease. in gii, the post therapy whole body scan showed pathological uptakes in all cases: in four patients in lungs, in four in mediastinum and in three in lateral neck. in two patients with mediastinum uptake, tg levels were undetectable after rhtsh. in the follow-up, two patients with lateral neck uptake were rendered disease free, four patients died (three due to thyroid cancer) and five out of the remaining patients have persistent disease. in conclusion, rhtsh aided therapy was helpful to eliminate normal thyroid bed remnants in 16/17 (94%) patients (gi). rhtsh stimulated tg was undetectable in two patients with mediastinal metastasis. we believe that rhtsh is a good alternative to levothyroxine withdrawal for the treatment of dtc with radioactive iodine, increasing the quality of life in these patients. caution should be recommended in the follow-up of unselected dtc patients only with stimulated tg levels.